India, Nov. 6 -- Pulse Biosciences, Inc. (PLSE) announced positive six-month interim results from its PRECISE-BTN study, which is evaluating the nPulse Vybrance Percutaneous Electrode System for treating symptomatic and overactive benign thyroid nodules.
The results were presented at the 95th Annual Meeting of the American Thyroid Association (ATA) in Philadelphia.
The interim results included 43 patients from three U.S. medical centers who had completed six months of follow-up.
Among these patients, 86% achieved at least a 50% reduction in thyroid nodule size, meeting the study's main goal. The median reduction in nodule volume was 72% at six months.
Patients also reported improvements in symptoms and quality of life. Overall quality-o...